Petti Mc
About
In The Last Decade
Petti Mc
24 papers receiving 759 citations
Peers
Comparison fields: 5 of 39
- Hematology 679
- Molecular Biology 596
- Public Health, Environmental and Occupational Health 185
- Biochemistry 97
- Genetics 86
Countries citing papers authored by Petti Mc
This map shows the geographic impact of Petti Mc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petti Mc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petti Mc more than expected).
Fields of papers citing papers by Petti Mc
This network shows the impact of papers produced by Petti Mc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petti Mc. The network helps show where Petti Mc may publish in the future.
Co-authorship network of co-authors of Petti Mc
This figure shows the co-authorship network connecting the top 25 collaborators of Petti Mc. A scholar is included among the top collaborators of Petti Mc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petti Mc. Petti Mc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | 129 | |
| 3 | Retrospective survival analysis of elderly patients with acute myeloid leukemia (AML) treated with aggressive or non aggressive therapy | 2 |
| 4 | 27 | |
| 5 | 196 | |
| 6 | Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen. | 5 |
| 7 | In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. | 42 |
| 8 | 30 | |
| 9 | Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. | 8 |
| 10 | Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group. | 3 |
| 11 | BAVC regimen in CR AML patients. | 1 |
| 12 | 68 | |
| 13 | In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. | 12 |
| 14 | Defective antibody-dependent and lectin-induced polymorphonuclear cytotoxicity in patients with myelodysplastic syndromes. | 1 |
| 15 | Treatment of recurrent promyelocytic leukemia with a combination regimen utilizing amsacrine, cytosine arabinoside and 6-thioguanine (AAT). | 3 |
| 16 | 44 | |
| 17 | Acute nonlymphocytic leukemia in the elderly: results of a retrospective study. | 8 |
| 18 | Acute non lymphoid leukemia treatment: an update. | 4 |
| 19 | Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. | 36 |
| 20 | Treatment of acute nonlymphocytic leukemia (ANLL) in elderly patients. Results of a multicentric study. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.